CN111494528A

CN111494528A - Traditional Chinese medicine composition for treating pulmonary heart disease

Info

Publication number: CN111494528A
Application number: CN202010416538.6A
Authority: CN
Inventors: 仲崇允
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-05-18
Filing date: 2020-05-18
Publication date: 2020-08-07
Also published as: CN113144073A

Abstract

The invention discloses a Chinese medicinal composition for treating chronic pulmonary heart disease, which belongs to an oral Chinese medicinal preparation and has the technical scheme that the Chinese medicinal composition is prepared into a dose of one day by using the following Chinese medicinal raw materials, namely 6 parts of schisandra chinensis; 10 parts of fried pepperweed seed, evergreen, moldavica dragonhead and grassleaf sweelflag rhizome respectively; 12 parts of red peony root; 30 parts of carpet bugle and cortex Syringae. The traditional Chinese medicine composition can be used for treating chronic pulmonary heart disease generally within 30 days, and can be recovered after 2-3 chronic pulmonary heart disease treatment courses, so that the treatment effect is remarkable. The clinical tracking of 100 persons shows that the total effective rate is 100 percent, the obvious effect is 86 percent, and the cure rate is 58 percent.

Description

Traditional Chinese medicine composition for treating pulmonary heart disease

Technical Field

The invention relates to the field of preparation of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic pulmonary heart disease.

Background

Chronic pulmonary heart disease is also called pulmonary heart disease, and is a heart disease which is caused by the abnormal structure and function of lung tissue caused by the chronic lesion of lung tissue, pulmonary artery blood vessels or thorax, leads to the increase of pulmonary vascular resistance, the increase of pulmonary artery pressure and the load of right ventricle, thus leading to the dilation and hypertrophy of right heart, accompanied or not accompanied by right heart congestive heart failure.

According to the statistics of 662 autopsy data of Chinese national pulmonary heart disease pathology scientific research cooperative group, the chronic obstructive pulmonary disease accounts for 81.8 percent of the causes of the Chinese pulmonary heart disease. Other diseases such as bronchial asthma, severe pulmonary tuberculosis, bronchiectasis, pneumoconiosis, interstitial lung disease, etc., and chronic pulmonary heart disease can be secondary in late stage.

Western medicine is mainly used for controlling infection and correcting heart and lung function failure. After controlling infection and improving respiratory function, most patients with right heart failure can only relieve cardiac insufficiency. Some patients still require the use of diuretics and/or cardiotonics.

Disclosure of Invention

The invention aims to provide an oral traditional Chinese medicine composition for treating chronic pulmonary heart disease, which has obvious effect on treating pulmonary heart disease caused by chronic bronchitis or chronic obstructive pulmonary disease.

According to traditional Chinese medicine, chronic pulmonary heart disease belongs to the categories of phlegm and fluid retention, lung distension, cough and asthma, water vapor, palpitation and the like in traditional Chinese medicine.

The traditional Chinese medicine considers that the pulmonary heart disease is mainly characterized by mutual influence of turbid phlegm and fluid retention and blood stasis. The cause of the disease is that the phlegm-fluid retention is caused by the repeated affection of exogenous pathogenic factors such as wind, cold, summer-heat and dampness, which leads to the invasion of cold-dampness, the failure of lung-defense to disperse, the invasion of damp-pathogen to the exterior of the body, the dampness encumbering the spleen-yang and the water-dampness retention. At first, lung qi deficiency is the main factor, and then qi and yin deficiency occurs. The lung-qi stagnation, spleen failure and transportation, body fluids failure to transform, and the failure of lung to transform into fluid, spleen deficiency, kidney deficiency to transform, turbid phlegm to recover and retention, and cough and asthma to continue, further aggravate the disease and develop into pulmonary heart disease.

The Chinese medicinal composition is prepared from Chinese traditional herbal medicines, and is a Chinese medicinal composition for effectively treating chronic pulmonary heart disease by orderly matching certain natural extracts with determined components and clear effects according to a plurality of principles of traditional Chinese medicine treatment based on syndrome differentiation and modern medicine.

1. The invention provides a traditional Chinese medicine composition for treating chronic pulmonary heart disease, which comprises fried semen lepidii, evergreen, moldavica dragonhead, grassleaf sweelflag rhizome, red paeony root, carpet bugle and cortex Syringae.

Further, 3-6 parts of schisandra chinensis; 5-10 parts of fried semen lepidii, evergreen, moldavica dragonhead and grassleaf sweelflag rhizome, 6-12 parts of red paeony root, and 15-30 parts of carpet bugle and Chinese cymbidium bark.

In a preferred embodiment, the traditional Chinese medicine composition for treating chronic pulmonary heart disease comprises the following raw material medicines in parts by weight:

6 parts of fructus schisandrae; 10 parts of fried pepperweed seed, evergreen, moldavica dragonhead and grassleaf sweelflag rhizome respectively; 15 parts of red peony root; 30 parts of carpet bugle and cortex Syringae.

Wherein, stir-frying semen lepidii: pungent taste; bitter; is cold. Entering the lung; a core; liver; the stomach; the bladder channel. Purging lung to reduce qi; eliminating phlegm and relieving asthma; inducing diuresis to alleviate edema; purge and eliminate pathogenic factors.

Root of Rohdea japonica Roth: bitter, sweet and cold in taste. Entering the lung; the heart meridian. Clearing away heat and toxic materials, tonifying heart, and promoting urination; cool blood and stop bleeding.

Red peony root: bitter and slightly cold in taste. It enters liver meridian. Clear heat and cool blood, dissipate blood stasis and alleviate pain.

And (3) fragrant blue: pungent, bitter and cool. Clear lung-heat, relieve exterior syndrome, cool liver and stop bleeding. Can be used for treating tracheitis, asthma, and heart disease.

Grassleaf sweelflag rhizome: pungent, bitter and warm. It enters heart and stomach meridians. Resolve dampness, stimulate appetite, induce resuscitation, eliminate phlegm, refresh mind and promote intelligence.

Cortex Syringae: bitter and slightly cold. Clear lung heat, dispel phlegm, relieve cough and asthma; to induce diuresis.

Ajuga reptans: bitter and cold in flavor. Clear heat and remove toxicity, cool blood and pacify liver. Can be used for treating bronchitis, pneumonia, and lung abscess.

Schisandra chinensis: a monosodium glutamate; and (4) temperature. It enters lung, heart and kidney meridians. Astringing, invigorating qi, promoting fluid production, invigorating kidney, calming heart, protecting and enhancing heart function, astringing lung, and relieving cough. Can be used for treating chronic cough, asthma, spontaneous perspiration, night sweat, body fluid deficiency and thirst due to deficiency of both lung and kidney.

Semen Lepidii is effective in tonifying heart and increasing coronary blood flow, and does not increase oxygen consumption of myocardium. Can be used for treating chronic pulmonary heart disease and asthma and swelling due to heart failure. Rohdea japonica has better effect on patients with pulmonary heart disease complicated with whole heart failure. The two are used together as monarch drug

The major link in the development of chronic pulmonary heart disease is pulmonary hypertension. Under the condition of pulmonary hypertension, pressure must be increased when the right ventricle contracts, and the pressure is long, so that the right ventricle is overloaded, the cardiac muscle is anoxic, the right heart is hypertrophic, and when the cardiac function is incomplete, the right heart failure phenomena such as liver enlargement, jugular vein anger, general edema and the like can occur. The moldavica dragonhead general flavone improves myocardial ischemia, reduces blood viscosity and platelet aggregation rate, can improve pulmonary hypertension caused by hypoxia, reduces oxidative stress, enhances an antioxidant mechanism, and has a certain protection effect on lung injury caused by a hypoxic environment. Radix Paeoniae Rubra has effects of dilating pulmonary blood vessel, improving pulmonary blood flow, reducing pulmonary hypertension and pulmonary vascular resistance, increasing cardiac output, and improving right heart function and blood rheological property of patients with cor pulmonale. Can obviously reduce the whole blood viscosity, the plasma viscosity and the hematocrit of patients with the pulmonary heart disease. The moldavica dragonhead and the red paeony root can effectively reduce pulmonary hypertension and pulmonary vascular resistance, improve myocardial anoxia and enhance the function of right heart, and are ministerial drugs.

The most prominent factor in the development of pulmonary hypertension is hypoxia. Chronic cor pulmonale often has serious respiratory failure, affects gas exchange, oxygen in the air cannot be inhaled, carbon dioxide in blood cannot be discharged, and patients usually have the phenomena of short breath, palpitation, cyanosis of lips and tips of fingers and the like. Rhizoma Acori Graminei has effects of relieving asthma and cough, and improving pulmonary ventilation function of patients with bronchial asthma and pulmonary heart disease. It also has effects in dilating coronary blood vessel, increasing coronary blood flow, and treating pulmonary heart disease due to turbid phlegm and qi stagnation. Fructus Schisandrae can smooth heart beat frequency, increase coronary blood flow, enhance and regulate energy metabolism of myocardial cells and arterioles of heart and kidney, and improve nutrition and function of myocardium. Fructus Schisandrae chinensis is beneficial to oxygen exchange of tissue cells, and has protective effect on anoxic heart tissue and damaged myocardial cells. The fructus Schisandrae chinensis can promote absorption, accelerate respiration, and significantly reduce blood pressure. Schisandra chinensis has the effect of eliminating phlegm and can obviously reduce cough frequency. The schisandra chinensis and the rhizoma acori graminei can effectively improve the hypoxia of heart and lung tissues and are ministerial drugs.

Intrapulmonary infections are often an important factor in promoting cardiac insufficiency. Fever during infection can increase cardiac burden; certain toxins may directly cause myocardial degeneration, necrosis; intrapulmonary infection can aggravate the original pathological changes of the lung, and seriously affect the function of pulmonary ventilation. Hypoxia of the body can also promote the occurrence and development of cardiac insufficiency. The cortex Syringae has obvious phlegm eliminating effect and obvious asthma relieving effect. Can relieve hypertrophy and hyperplasia of bronchial epithelial cells below grade III, reduce the number of bronchial goblet cells at each grade, relieve hypertrophy and hyperplasia of tracheal glands, and reduce the number of acinus and duct adhesion and liquefaction. For chronic bronchitis, bronchial asthma; has remarkable curative effect on cardiac edema. The carpet bugle has strong heat-clearing and detoxifying effects, and the flavonoid glycoside can reduce the permeability of the trachea during inflammation, thereby playing a role in obviously diminishing inflammation and eliminating phlegm. Wherein the flavonoid glycoside can directly inhibit cough center, and has similar cough relieving effect intensity with codeine; the flavonoid glycoside has strong anti-infection effect, can directly dilate bronchial smooth muscle, and can resist histamine induced bronchial smooth muscle contraction. The asthma relieving effect of 250mg/kg flavonoid glycoside is equal to 125mg/kg aminophylline; has effects in enhancing immunity and inhibiting pneumococcus. The cortex Syringae and herba Ajugae are used together as adjuvant drugs for effectively treating intrapulmonary infection.

The traditional Chinese medicine composition has the effects of strengthening body resistance and tonifying deficiency, activating blood circulation to dissipate blood stasis, relieving cough and asthma, clearing lung and eliminating phlegm and improving the immunity of a patient, can penetrate through the whole process of treating the pulmonary heart disease, and can help the patient to improve symptoms, relieve pain and quickly recover the patient. After long-term administration, patients have no adverse reaction, blood is tracked and checked normally, and the curative effect is exact and does not rebound.

The treatment cost of the invention is relatively low and is far lower than that of western medicine.

The traditional Chinese medicine formula disclosed by the invention has the effect of fundamentally solving the problem, takes effect in one month, can obviously improve the chronic pulmonary heart disease in three months, and basically recovers the function in six months. The traditional Chinese medicine is used for treating 100 patients in clinical application, the prescription is used for treating, one dose is taken every day, 100 ml of water is decocted, the decoction is divided into two parts, one part is taken in the morning and one part is taken at night, and one month is a period; the total effective rate is 100%, the obvious effect is 86%, and the cure rate is 58%.

The invention also provides an oral preparation prepared from the traditional Chinese medicine composition for treating the disease, wherein the oral preparation comprises oral liquid, tablets, capsules, pills and the like, preferably the dosage forms are tablets and capsules, and one dose is taken every day in the morning and at night.

The traditional Chinese medicine composition can be prepared into various dosage forms. For example, the decocted liquid medicine is sterilized and disinfected and then packaged to prepare oral liquid; or concentrating the decoction, oven drying, adding pharmaceutically acceptable adjuvants, and making into tablet, capsule, pill, etc.

The medically acceptable auxiliary materials comprise starch, dextrin, sodium carboxymethylcellulose, polyethylene glycol, calcium hydrophosphate, sodium alginate, potassium sorbate and the like.

The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention in any way, and it will be apparent to those skilled in the art that the above description of the present invention can be applied to various modifications, equivalent variations or modifications without departing from the spirit and scope of the present invention.

Claims

1. A traditional Chinese medicine composition for treating chronic pulmonary heart disease is characterized by comprising fructus schisandrae, parched semen lepidii, evergreen, moldavica dragonhead, rhizoma acori graminei, radix paeoniae rubra, ajuga reptans and cortex Syringae.

2. The traditional Chinese medicine composition for treating chronic pulmonary heart disease according to claim 1, wherein the schisandra chinensis is 3-6 parts; 5-10 parts of fried semen lepidii, evergreen, moldavica dragonhead and grassleaf sweelflag rhizome, 6-12 parts of red paeony root, and 15-30 parts of carpet bugle and Chinese cymbidium bark.

3. The traditional Chinese medicine composition for treating chronic pulmonary heart disease according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 6 parts of fructus schisandrae; 10 parts of fried pepperweed seed, evergreen, moldavica dragonhead and grassleaf sweelflag rhizome respectively; 12 parts of red peony root; 30 parts of carpet bugle and cortex Syringae.

4. An oral formulation for treating cor pulmonale, which is prepared from the Chinese medicinal composition of any one of claims 1 to 3.